Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
PLIANT THERAPEUTICS, INC. (PLRX)
|
Add to portfolio |
|
|
|
| Price: |
$13.55
| | Metrics |
| OS: |
59.8
|
M
| |
-27
|
% ROE
|
| Market cap: |
$811
|
M
| |
-32
|
% ROIC
|
|
Net cash:
|
$545
|
M
| |
$9.11
|
per share
|
|
EV:
|
$266
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($157)
|
M
| |
|
|
|
EBIT
|
($159)
|
M
| |
|
|
| EPS |
($2.85)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 9.7 | 7.6 | 41.8 | 57.1 | -24.4 |
| Revenue growth | 27.9% | -81.9% | -26.7% | -333.7% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | -92.7 |
| Gross profit | 9.7 | 7.6 | 41.8 | 57.1 | 68.3 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | -279.9% |
| Research and development | 96.9 | 77.5 | 66.2 | 47.4 | |
| General and administrative | 39.9 | 27.6 | 17.3 | 10.9 | 6.5 |
| EBIT | -127.2 | -97.5 | -41.6 | -1.2 | -30.9 |
| EBIT margin | -1313.4% | -1288.1% | -99.6% | -2.2% | 126.6% |
| Pre-tax income | -123.3 | -97.3 | -41.5 | -0.6 | -30.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -123.3 | -97.3 | -41.5 | -6.9 | 0.0 |
| Net margin | -1273.3% | -1284.5% | -99.3% | -12.0% | 0.1% |
| |
| Diluted EPS | ($2.94) | ($2.71) | ($1.95) | ($4.22) | ($30.16) |
| Shares outstanding (diluted) | 42.0 | 35.8 | 21.3 | 1.6 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|